Generic manufacturer Mylan will not sell Dey L.P., its specialty pharmaceutical division. After a review, the company decided Dey L.P. would be positive for earnings through 2010.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.